

June 30, 2023
Web Announcement 3108

Drug Use Review (DUR) Board Approves Changes for Physician Administered Drugs (PAD)

The Nevada Medicaid Drug Use Review (DUR) Board met on April 20, 2023 and voted to approve the following changes for physician administered drugs (PAD). The PAD Prior Authorization Program will take effect on July 1, 2023 (see [web announcement 3041](#) for full details).

Drug Class/Program	Changes
Abraxane® (paclitaxel protein-bound particles)	Approval of new clinical criteria
Bavencio® (avelumab)	Approval of new clinical criteria
Beovu® (brolucizumab-dbll)	Approval of new clinical criteria
bevacizumab	Approval of new clinical criteria
Darzalex® (daratumumab)	Approval of new clinical criteria
Darzalex Faspro® (daratumumab and hyaluronidase-fihj)	Approval of new clinical criteria
Elaprase® (idursulfase)	Approval of new clinical criteria
Eylea® (aflibercept)	Approval of new clinical criteria
Imfinzi® (durvalumab)	Approval of new clinical criteria
intravenous Immune Globulin (IVIG)	Approval of new clinical criteria
Jemperli® (dostarlimab-gxly)	Approval of new clinical criteria
Kadcyla® (ado-trastuzumab emtansine)	Approval of new clinical criteria
Keytruda® (pembrolizumab)	Approval of new clinical criteria

Libtayo® (cemiplimab-rwlc)	Approval of new clinical criteria
----------------------------	-----------------------------------

Prior Authorization forms may be found on the below webpages:
<https://www.mrxgateway.com/> (medical pharmacy/physician administered drugs)